Local Anesthetic Inhibition of m1 Muscarinic Acetylcholine Signaling
- 1 August 2000
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anesthesiology
- Vol. 93 (2), 497-509
- https://doi.org/10.1097/00000542-200008000-00030
Abstract
Background Local anesthetics inhibit lipid mediator signaling (lysophosphatidate, thromboxane) by acting on intracellular domains of the receptor or on the G protein. On receptors for polar agonists, the ligand-binding pocket could form an additional site of interaction, possibly resulting in superadditive inhibition. The authors therefore investigated the effects of local anesthetics on m1 muscarinic receptor functioning. Methods The authors expressed receptors in isolation using Xenopus oocytes. Using a two-electrode voltage clamp, the authors measured the effects of lidocaine, QX314 (permanently charged), and benzocaine (permanently uncharged) on Ca2+-activated Cl- currents elicited by methylcholine. The authors also characterized the interaction of lidocaine with [3H] quinuclydinyl benzylate ([3H]QNB) binding to m1 receptors. Results Lidocaine inhibited muscarinic signaling with a half-maximal inhibitory concentration (IC50 18 nm) 140-fold less than that of extracellularly administered QX314 (IC50 2.4 microm). Intracellularly injected QX314 (IC50 0.96 mm) and extracellularly applied benzocaine (IC50 1.2 mm) inhibited at high concentrations only. Inhibition of muscarinic signaling by extracellularly applied QX314 and lidocaine was the result of noncompetitive antagonism. Intracellularly injected QX314 and benzocaine inhibited muscarinic and lysophosphatidate signaling at similar concentrations, suggesting an action on the common G-protein pathway. Combined administration of intracellularly injected (IC50 19 microm) and extracellularly applied QX314 (IC50 49 nm) exerted superadditive inhibition. Lidocaine did not displace specific [3H]QNB binding to m1 receptors. Conclusions m1 Muscarinic signaling is inhibited by clinically relevant concentrations of lidocaine and by extracellularly administered QX314, suggesting that the major site of action is a extracellular domain of the muscarinic receptor. An additional less potent but superadditive inhibitory effect on the G-protein is suggested.Keywords
This publication has 34 references indexed in Scilit:
- Synergistic Inhibition of Lysophosphatidic Acid Signaling by Charged and Uncharged Local AnestheticsAnesthesia & Analgesia, 1999
- Volatile anaesthetics have differential effects on recombinant m1 and m3 muscarinic acetylcholine receptor functionBritish Journal of Anaesthesia, 1998
- Local Anesthetic Effects on Thromboxane A2 signalingAnesthesiology, 1998
- Dose‐dependent suppression of the neutrophil respiratory burst by lidocaineActa Anaesthesiologica Scandinavica, 1998
- Inhibition of Lysophosphatidate Signaling by Lidocaine and BupivacaineAnesthesiology, 1997
- Inhibition by Ketamine of Muscarinic Acetylcholine Receptor FunctionAnesthesia & Analgesia, 1995
- Halothane Inhibits Signaling through m1 Muscarinic Receptors Expressed in Xenopus OocytesAnesthesiology, 1995
- Molecular Mechanisms of Local AnesthesiaAnesthesiology, 1990
- Batrachotoxin changes the properties of the muscarinic receptor in rat brain and heart: possible interaction(s) between muscarinic receptors and sodium channels.Proceedings of the National Academy of Sciences of the United States of America, 1985
- Interactions of D600 (methoxyverapamil) and local anesthetics with rat brain α-adrenergic and muscarinic receptorsBiochemical Pharmacology, 1980